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A randomised phase III trial was conducted to assess the role of interferon-alpha (INFa) 2a as maintenance therapy following surgery
and/or chemotherapy in patients with epithelial ovarian carcinoma. Patients were randomised following initial surgery/chemotherapy
to interferon-alpha 2a as 4.5 mega-units subcutaneously 3 days per week or to no further treatment. A total of 300 patients were
randomised within the study between February 1990 and July 1997. No benefit for interferon maintenance was seen in terms of
either overall or clinical event-free survival. We conclude that INF-a is not effective as a maintenance therapy in the management of
women with ovarian cancer. The need for novel therapeutics or strategies to prevent the almost inevitable relapse of patients despite
increasingly effective surgery and chemotherapy remains.
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Although epithelial ovarian cancer is a relatively chemosensitive
disease, the disease ultimately relapses and leads to the death of
most patients. The median duration of remission following first-
line chemotherapy with platinum/taxane combinations for patients
with advanced disease is between 12 and 24 months. A variety of
strategies have been employed to maintain the benefits achieved
with chemotherapy in advanced ovarian cancer. The dose and
duration of chemotherapy have both been increased, but increases
in response rates have not been associated with improvement in
survival (Eltabbakh et al, 1998; Umesaki et al, 1999; McGuire,
2000).
The concept of additional therapy to maintain the response
achieved with chemotherapy has been assessed in a number of
disease and clinical settings. In the 1980s, interferon-alpha (INFa)
was assessed as a maintenance therapy for patients with multiple
myeloma. As a single agent, interferon has a low response rate in
myeloma patients with responses of approximately 15%. However,
in patients who demonstrated no evidence of disease progression
following primary chemotherapy, maintenance therapy with low-
dose subcutaneous INFa improved progression-free and overall
survival (Mandelli et al, 1990).
Interferon-a has limited activity in active advanced ovarian
cancer (Freedman et al, 1983; Einhorn et al, 1988). However, we
hypothesised that subcutaneous INFa may act as an effective
maintenance therapy in patients with advanced ovarian cancer
and thus improve overall survival. To test this hypothesis,
a prospective randomised trial was performed in patients with
FIGO stage Ic–IV epithelial ovarian cancer, in whom no evidence
of disease progression was seen following surgery and/or
chemotherapy.
PATIENTS AND METHODS
The study was approved by the Local Research Ethics Committee
of each participating centre and written informed consent was
obtained prior to randomisation. Patients eligible for the study had
histologically proven epithelial ovarian cancer that showed no
evidence of disease progression (on clinical, radiological or CA-125
assessment) following postoperative chemotherapy. Patients were
randomised within 8 weeks of completing chemotherapy to
treatment with INF-a 2a (Roferon-A, Roche) (4.5 mega-units
subcutaneously 3 days per week) or to a no maintenance treatment
control group. Interferon was continued until disease progression,
or in response to toxicity or patient request. The study was
designed to detect a 50% increase in median survival and therefore
required 300 randomised patients. The trial profile is shown in
Figure 1.
To further analyse the effect of maintenance interferon, the
disease status of each patient was determined following surgery
and/or chemotherapy. Patients in whom there was no evidence of
disease either clinically or radiologically following surgery and/or
chemotherapy were designated as disease-free (DF). Those patients
in whom disease was apparent clinically or radiologically followingReceived 16 February 2004; revised 5 May 2004; accepted 5 May 2004
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Figure 1 Trial profile.
Table 1 Patient characteristics by treatment group
Interferon Observation
(n¼ 149) (n¼ 149)
Median (range) age at diagnosis (years) 58 (31–76) 57 (33–78)
FIGO stage at diagnosis
I 11 (7%) 12 (8%)
II 22 (14%) 19 (13%)
III 94 (63%) 95 (64%)
IV 22 (15%) 23 (15%)
Residual disease following surgery (cm)
0 23 (18%) 26 (20%)
o2 44 (35%) 51 (40%)
2–5 24 (19%) 13 (10%)
45 36 (28%) 40 (31%)
Histology
Serous 67 (45%) 72 (48%)
Mucinous 10 (7%) 12 (8%)
Endometrioid 27 (18%) 34 (23%)
Clear cell 4 (3%) 4 (3%)
Other 20 (13%) 10 (7%)
Undifferentiated 3 (2%) 2 (1%)
Not stated 18 (12%) 15 (10%)
Tumour grade
1 11 (9%) 14 (11%)
2 47 (38%) 43 (33%)
3 66 (53%) 75 (57%)
Not stated 25 17
WHO performance status pre-chemotherapy
0 84 (60%) 83 (56%)
1 46 (32%) 46 (31%)
2 7 (4%) 17 (12%)
3 3 (2%) 1 (1%)
4 3 (2%) 0
Not stated 6 2
Chemotherapy regimen
Platinum single agent 89 (60%) 88 (59%)
Platinum combination 44 (29%) 37 (25%)
Platinum/taxane 15 (10%) 20 (13%)
Taxane single agent 0 1 (1%)
Other single agent 1 (1%) 3 (2%)
Response to surgery and/or chemotherapy
Disease free 89 (61%) 95 (65%)
Disease present 58 (39%) 52 (35%)
Not evaluable 2 2
CA125 after surgery and/or chemotherapy
o35 U ml1 47 (77%) 62 (78%)
35–65 U ml1 2 (3%) 9 (11%)
65–200 U ml1 8 (13%) 5 (6%)
4200 4 (7%) 4 (5%)
Not stated 88 69
WHO performance status at randomisation
0 113 (76%) 114 (79%)
1 32 (22%) 28 (19%)
2 3 (2%) 2 (1%)
3 0 0
4 0 0
Not stated 1 5
Table 1 (Continued)
Interferon Observation
(n¼ 149) (n¼ 149)
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surgery and/or chemotherapy were designated as disease-present
(DP).
For additional detail regarding patient selection, dose modifica-
tions, study design and statistical methods, see supplementary
information.
RESULTS
Between February 1990 and July 1997, 300 patients were
randomised by 23 consultants from 14 centres across the UK
(for participating centres and consultants, see supplementary
information), 151 to observation, 149 to interferon. The patients in
the two treatment arms were similar with respect to baseline
characteristics (Table 1). The median follow-up time for interferon
patients was 27.0 months (range 2.3–149.7), and for observation
patients 32.2 months (range 1.7–141.7). Eight patients (two
interferon and six observation) died without attending any
follow-up visits. Of the 149 patients randomised to receive
maintenance INFa, 144 received at least one injection (see
supplementary information). The duration of treatment and the
reason for stopping is shown in Table 2. Figure 4 shows
compliance with interferon maintenance over time in those
patients who remained progression free. The most commonly
reported toxicity/adverse event for both interferon and observa-
tion patients was fatigue (72 and 46%, respectively) (Table 3). Dose
modification of interferon was made in 18 (12.5%) patients due to
toxicity.
No benefit for interferon maintenance was seen in terms of
either overall or clinical event-free survival. The median overall
survival in the interferon arm was 27.0 months and in the
observation arm 32.7 months. The median clinical event-free
survival in the interferon arm was 10.3 months and 10.4 months in
the observation arm. The Kaplan– Meier survival curves for overall
and clinical event-free survival (Figure 2 and Figure 3) showed no
significant difference (overall survival – unadjusted HR¼ 1.06,
95% C.I.¼ 0.82– 1.38, Log-rank test P¼ 0.65; clinical event-free
survival – unadjusted HR¼ 0.96, 95% C.I.¼ 0.75– 1.22, Log-rank
test P¼ 0.73). When hazard ratios were adjusted for prognostic
factors previously defined, the results were similar.
The effect of treatment on overall survival and clinical event-free
survival was compared separately among patients who were DF
after surgery and/or chemotherapy and those who had DP after
surgery and/or chemotherapy. This comparison was unplanned
and performed only as a hypothesis generating analysis. No
significant differences for interferon maintenance were identified
(DF patients – clinical event-free survival – unadjusted HR¼ 0.88,
95% C.I.¼ 0.63– 1.22).
The multivariate analysis of prognostic factors and treatment
received, performed on the 298 patients in the intention to treat
population (Table 4), demonstrated that receiving interferon
maintenance was not related to either overall or clinical event-
free survival (see supplementary information).
Table 2 Duration of interferon treatment and reason for stopping
treatment
Number of
patients
Median (range) time
(in months) on
interferon
All patients 144 5 (o1–88)
Interferon stopped
Disease progression 61 8 (1–66)
Toxicity 50 3 (o1–37)
Patient desire 14 7 (o1–48)
Other 8 38 (1–71)
Death of patient 4 8 (3–14)
Not stated 4 22 (7–51)
Treatment status unknown at last review 3 54 (51–88)
Table 3 Adverse events/toxicity (all grades)
Interferon Observation
(n¼ 144) (n¼ 149) Significance
Toxicity/adverse event
Flu-like symptoms 102 (69%) 47 (31%) Po0.001
Fatigue 106 (71%) 71 (47%) Po0.001
Nausea/vomiting 61 (41%) 52 (34%) Not significant
Neurological 6 (4%) NR —
Dyspnoea 9 (6%) NR —
Depression/anxiety 9 (6%) NR —
Skin change/rash 7 (5%) NR —
Alopecia 7 (5%) NR —
Arthalgia/arthritis 4 (3%) NR —
Insomnia 3 (2%) NR —
Haematological 3 (2%) NR —
Hepatic 1 (1%) NR —
Injection site reaction 2 (1%) NR —
Other 19 (13%) NR —
Not stated 4 (3%) NR —
NR¼ not recorded.
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Figure 2 Overall survival by randomised treatment group.
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Figure 3 Clinical event-free survival by randomised treatment group.
Table 4 Multivariate analysis of treatment received and prognostic factors for overall and clinical event-free survival (n¼ 298)
Overall survival Clinical event-free survival
Adjusted HR (95% C.I.) P Adjusted HR (95% C.I.) P
Randomised treatment
Observation 1.00 1.00
Interferon 1.10 (0.83–1.45) 0.51 0.92 (0.71–1.20) 0.55
Response–11 treatment
Disease-free 1.00 1.00
Disease-present 1.53 (1.12–1.65) 0.01 1.84 (1.37–2.49) o0.001
Age at diagnosis (years)
o55 1.00 1.00
55–65 1.51 (1.10–2.07) 1.13 (0.83–1.52)
465 1.36 (0.92–2.01) 0.034 1.14 (0.79–1.65) 0.67
FIGO stage
Ic 1.00 1.00
II 0.80 (0.33–2.74) 1.02 (0.51–2.06)
III 2.11 (1.04–4.29) 2.48 (1.28–4.80)
IV 2.82 (1.32–6.03) o0.001 2.92 (1.42–5.59) o0.001
WHO performance status
0 1.00 1.00
1 1.16 (0.82–1.65) 1.16 (0.82–1.65)
2/3/4 1.74 (1.22–2.49) 0.035 1.74 (1.22–2.49) 0.62
Size of residual disease
0 1 1
o2 cm 1.02 (0.63–1.64) 1.02 (0.63–1.64)
42 cm 1.10 (0.67–2.44) 1.09 (0.67–1.77)
Not stated 1.69 (0.97–2.93) 0.17 1.69 (0.97–2.93) 0.74
Tumour type
Serous 1.00 1.00
Mucinous 1.32 (0.78–2.22) 1.15 (0.68–1.93)
Endometrioid 1.16 (0.79–1.70) 1.06 (0.72–1.56)
Clear cell 1.69 (0.65–4.41) 1.39 (0.49–3.93)
Other 0.86 (0.53–1.40) 0.89 (0.56–1.43)
Undifferentiated 1.09 (0.37–3.81) 1.36 (0.52–3.57)
Not stated 1.59 (1.00–2.43) 0.33 1.39 (0.87–2.21) 0.74
Tumour grade
Well differentiated 1.00 1.00
Moderately differentiated 0.83 (0.45–1.54) 0.87 (0.54–1.52)
Poorly differentiated 1.33 (0.73–2.41) 1.32 (0.77–2.24)
Not stated 0.92 (0.46–1.84) 0.033 0.85 (0.45–1.60) 0.038
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DISCUSSION
This trial was designed to determine whether the use of low-dose
subcutaneous INFa could improve the overall survival of patients
with epithelial ovarian cancer following primary therapy with
surgery and/or chemotherapy. Patients with all stages of disease at
presentation and with no evidence of disease progression after
primary therapy were randomised within the trial. The overall and
clinical event-free survival of ovarian cancer patients studied
within this trial was typical of results obtained with platinum
combination chemotherapy in the 1990s. However, survival times
were not improved by the addition of maintenance low-dose
subcutaneous IFNa following primary therapy.
Interferon-a has been shown to have an in vitro activity against
ovarian cancer cell lines (Epstein et al, 1980) and a limited clinical
benefit in advanced ovarian cancer (Freedman et al, 1983; Einhorn
et al, 1988). Clinical studies have assessed the effect of
intraperitoneal INFa in a number of phase II studies both after
and in combination with platinum chemotherapy (Berek et al,
1985; Nardi et al, 1990; Willemse et al, 1990; Bruzzone et al, 1997;
Berek et al, 1999). These studies have confirmed that such a
treatment can be delivered although its benefit over standard
treatment has not been assessed. No clinical trial of subcutaneous
INFa in ovarian cancer has previously been reported. However, an
alternative immunoregulatory cytokine, interferon-g has been
assessed in a randomised phase III trial as an addition to primary
chemotherapy with cisplatin and cylophosphamide (Windbichler
et al, 2000). This showed a significant improvement in progres-
sion-free survival. However, improvements in clinical response
rate and overall survival did not achieve statistical significance.
Experience with biological therapy has suggested that the
benefits of such therapy are often seen in patients with small
volume or clinically undetectable disease. Although this effect has
also been seen in previous trials of cytokine therapy in ovarian
cancer (Berek et al, 1985; Pujade-Lauraine et al, 1996), the recent
study of interferon-g showed equal efficacy in patients with both
small and large volume disease (Windbichler et al, 2000). To
mirror the initial study of interferon maintenance in myeloma,
patients with no evidence of disease progression following primary
therapy were randomised and therefore, many patients with
residual disease were randomised. However, a subgroup analysis
of the patients in complete clinical remission within this study
failed to identify a significant benefit for those patients.
Compliance with interferon maintenance was poor (Figure 4). At
6 months, only 67% of patients with no evidence of disease
progression remained on interferon maintenance. This is likely to
be due to the fact that this cohort of patients had undergone both
surgical intervention and chemotherapy prior to commencing
interferon treatment. This is in contrast to studies in myeloma,
renal cancer and melanoma in which treatment rarely follows both
extensive surgery and chemotherapy. Pegylated interferon has
recently been introduced into clinical trials. The half-life of these
modified forms of interferon are significantly increased allowing
weekly administration. It may be that the use of such treatment
would improve compliance by reducing both the frequency of
administration and the toxicity associated with the treatment.
Despite modern chemotherapy combinations, the natural
history of ovarian carcinoma remains one of relapse following
initial response to chemotherapy. A potential benefit for main-
tenance paclitaxel chemotherapy for some patients with ovarian
cancer has recently been reported although at the cost of clinically
significant toxicity (Markman et al, 2003). The need for an
effective nontoxic maintenance therapy is clear. This study has
demonstrated that subcutaneous INF-a given following surgery
and chemotherapy is not the answer to this ongoing dilemma.
However, the recent development of new, targeted molecular
therapies may allow the concept of maintenance therapy to be
examined further.
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